Statements Of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities
Net loss	$ (3,334,653)	$ (10,820,655)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	412,793	276,618
Amortization of intangibles	149,491	149,490
Amortization of deferred finance costs	74,793	163,034
Share-based compensation	625,854	822,785
Gain on debt extinguishment		(5,632,171)
Noncash interest		485,857
Loss on asset disposal	20,772
Adjustment of warrants	1,029,479	9,685,850
Changes in operating assets and liabilities:
Accounts receivable	617,873	1,494,116
Inventories	775,577	(872,083)
Prepaid expenses and other current assets	(46,427)	(81,867)
Other assets	(7,105)	(11,282)
Accounts payable	(889,868)	1,018,677
Accrued liabilities	(979,526)	(834,799)
Deferred revenue	(2,497,775)	(2,387,250)
Other liabilities	176,905	112,610
Net cash used in operating activities	(3,871,817)	(6,431,070)
Cash flows from investing activities
Purchase of fixed assets	(72,082)
Net cash used in investing activities	(72,082)
Cash flows from financing activities
Payments of deferred financing costs	(100,000)	(100,000)
Proceeds from revolving line of credit		7,650,000
Payments of revolving line of credit		(7,650,000)
Payments of Healthcare Royalty Partners debt		(13,020,780)
Proceeds from issuance of stock, net of issuance costs	29,573	23,203,051
Net cash provided by (used in) financing activities	(70,427)	10,082,271
Net increase (decrease) in cash and cash equivalents	(4,014,326)	3,651,201
Cash and cash equivalents at beginning of period	8,501,392	5,593,582
Cash and cash equivalents at end of period	$ 4,487,066	$ 9,244,783